India to France: Albendazole Export Trade Route

To import Albendazole formulations into France, the following approvals and registrations are necessary:

• Marketing Authorization (MA): A valid MA is mandatory for all medicinal products entering the EU market. Applicants must submit a comprehensive dossier in the Common Technical Document (CTD) or electronic CTD (eCTD) format, detailing quality, safety, and efficacy data.

• Dossier Submission: The CTD/eCTD dossier should include:
• Module 1: Administrative and product information
• Module 2: Summaries of quality, non-clinical, and clinical data
• Module 3: Quality (pharmaceutical documentation)
• Module 4: Non-clinical study reports
• Module 5: Clinical study reports

• Approval Timelines: The approval process duration varies based on the chosen procedure:
• Centralized Procedure: Approximately 210 days
• Decentralized Procedure (DCP): Around 210 days
• Mutual Recognition Procedure (MRP): About 90 days

• Product Registration Fees: Fees are contingent on the procedure and product specifics. For instance, the EMA's fee for a centralized MA application is approximately €296,900.

• GMP Inspection Requirements: Manufacturing facilities outside the EU, including those in India, must comply with EU Good Manufacturing Practice (GMP) standards. The EMA or national competent authorities conduct inspections to verify compliance.

Indian manufacturers exporting Albendazole formulations to France must meet stringent quality and GMP standards:

• GMP Certifications: Facilities must possess valid EU GMP certification, confirming adherence to EU standards. This certification is obtained through successful inspections by EU authorities.

• Approved Indian Facilities: As of August 2024, Indoco Remedies Limited received WHO prequalification for Albendazole Tablets, Chewable 400mg, indicating compliance with international quality standards.

• Recent Inspections and Regulatory Actions: In August 2024, WHO prequalified Albendazole Tablets, Chewable 400mg, manufactured by Indoco Remedies Limited, reflecting adherence to quality standards.

Several regulatory changes between 2024 and 2026 have impacted Indian pharmaceutical exports to France:

• WHO Prequalification: In August 2024, WHO prequalified Albendazole Tablets, Chewable 400mg, produced by Indoco Remedies Limited, enhancing market access and credibility.

• GMP Compliance Emphasis: In 2025, the EMA reinforced the necessity for non-EU manufacturers to comply with EU GMP standards, emphasizing the importance of maintaining valid certifications for market access.

Staying informed about these developments is crucial for Indian exporters to ensure compliance and maintain uninterrupted access to the French pharmaceutical market.

In 2024, the global Albendazole market was valued at approximately $11.67 billion, with projections indicating growth to $12.81 billion by 2025. While specific figures for France are not readily available, the country's demand for Albendazole formulations is influenced by several factors:

• Disease Prevalence: France's healthcare system addresses parasitic infections, including those treated by Albendazole.

• Healthcare Spending: France's healthcare expenditure supports the availability and accessibility of medications like Albendazole.

• Aging Population: An aging demographic may lead to increased susceptibility to certain infections, potentially elevating the demand for Albendazole formulations.

• Universal Health Coverage: France's comprehensive health coverage ensures that essential medications, including Albendazole, are accessible to the population.

Regarding supply, France imports Albendazole formulations from various countries, including India, and also relies on domestic pharmaceutical manufacturing to meet its needs.

Pharmaceutical products under HS code 30049099, such as Albendazole formulations, are subject to a 0% Most-Favored-Nation (MFN) import duty rate in France. Additionally, these products are exempt from Value Added Tax (VAT) and other import charges, facilitating their importation and availability within the French market. There are no Free Trade Agreements (FTAs) between India and France specifically affecting pharmaceutical tariffs, nor are there any anti-dumping duties imposed on Albendazole formulations imported into France.

India is a significant supplier of Albendazole formulations to France, accounting for $5.8 million in trade value, representing 8.0% of India's total Albendazole formulation exports. The top Indian exporters include:

1. 1Indoco Remedies Limited ($1.8 million)
2. 2Caplin Point Laboratories Limited ($0.5 million)
3. 3Niya Healthcare Private Limited ($0.5 million)
4. 4Croient Pharma Private Limited ($0.4 million)
5. 5Lincoln Pharmaceuticals Ltd ($0.3 million)

The primary buyers in France are:

1. 1Planet Pharma ($1.6 million)
2. 2Piex Societe Pharmaceutique ($0.5 million)
3. 3Balguerie ($0.4 million)

Other major countries supplying Albendazole formulations to France include China and various European Union manufacturers. India's competitive pricing, coupled with its robust pharmaceutical manufacturing capabilities, positions it favorably against competitors. The cost-effectiveness of Indian Albendazole formulations, without compromising quality, enhances their appeal in the French market.

India is a leading global producer of generic pharmaceuticals, accounting for approximately 20% of the world's supply by volume. This extensive manufacturing base includes a significant capacity for producing finished dosage forms containing Albendazole, such as tablets, capsules, and syrups. The country's cost-effective production is attributed to economies of scale, a skilled workforce, and a well-established supply chain. As of March 2026, India boasts over 400 WHO-GMP certified facilities and more than 200 US FDA-approved plants capable of producing Albendazole formulations, ensuring compliance with stringent international quality standards.

When comparing Albendazole formulations from India, China, and the European Union, several factors emerge:

• Cost: Indian manufacturers offer Albendazole formulations at a competitive price point, often 30-40% lower than European counterparts and approximately 20% less than Chinese producers.

• Quality Perception: Indian pharmaceutical products are widely recognized for their adherence to international quality standards, with numerous facilities holding WHO-GMP and US FDA certifications. Chinese manufacturers have made significant strides in quality but occasionally face scrutiny over compliance issues. European producers maintain high-quality standards but at a higher cost.

• Regulatory Acceptance in France: Indian Albendazole formulations are well-accepted in France, with several products registered and approved by the French National Agency for Medicines and Health Products Safety (ANSM). Chinese products face more rigorous scrutiny, while European formulations are inherently accepted but come with higher costs.

• Supply Reliability: India has a robust track record of reliable supply chains for pharmaceutical exports, including Albendazole formulations. China's supply reliability has improved but can be affected by regulatory interventions. European suppliers offer reliability but at a premium price.

The India-France supply chain for Albendazole formulations is characterized by:

• Manufacturing Capacity: Indian facilities have substantial capacity for producing Albendazole finished dosage forms, with some plants capable of manufacturing over 300 million tablets per month.

• Packaging and Cold Chain Capabilities: Indian manufacturers possess advanced packaging technologies and robust cold chain logistics, ensuring product stability and compliance with international shipping standards.

• Regulatory Compliance Track Record: Indian pharmaceutical companies have a strong history of compliance with international regulatory standards, including those of the US FDA and WHO-GMP.

• Capacity Constraints or Expansion Plans: Leading Indian manufacturers are continually expanding their production capacities to meet growing global demand, with several new facilities coming online in 2025 and 2026.

For French buyers sourcing Albendazole formulations from India, consider the following strategies:

• Dual-Sourcing Strategy: Engage with multiple Indian suppliers to mitigate risks associated with supply disruptions and ensure a consistent supply chain.

• Minimum Order Quantities (MOQs): Be aware that MOQs can vary among suppliers; negotiate terms that align with your demand forecasts and storage capabilities.

• Payment Terms: Standard payment terms in India-France pharmaceutical trade often include a 30-60 day credit period; establish clear agreements to maintain cash flow efficiency.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits, quality control assessments, and compliance checks, to ensure suppliers meet your quality and regulatory requirements.

• Regulatory Documentation: Ensure that suppliers provide comprehensive regulatory documentation, including Certificates of Analysis (CoA), WHO-GMP certificates, and any necessary approvals from French regulatory authorities.

Cost Estimates and Timeline:

• Audit Visits to India:
• Cost: Approximately €10,000–€15,000 per audit, covering travel, accommodation, and professional fees.
• Timeline: Planning and execution typically require 6–8 weeks, including scheduling, travel, on-site inspection, and reporting.

By adhering to this comprehensive framework, French pharmaceutical companies can effectively qualify Indian suppliers of Albendazole formulations, ensuring compliance with EU regulations and maintaining high-quality standards.